Analytic Tool Aiding Clinical Studies of Ganetespib for Advanced Ovarian Cancers

Analytic Tool Aiding Clinical Studies of Ganetespib for Advanced Ovarian Cancers
Parsortix, a system developed by Angle to harvest circulating tumor cells from a cancer patient's blood, is being used as part of the GANNET 53 clincial project that is testing the efficacy of Ganetespib's in the treatment of advanced ovarian cancers. If the project is successful, Parsortix could be used as a companion diagnostic to identify patients who respond to Ganetespib treatment. The GANNET 53 project, funded by the European Union, is evaluating in clinical trials the safety and efficacy of Ganetespib in combination with standard chemotherapy (Paclitaxel) in metastatic ovarian cancer patients. It began in 2013 and is expected to finish by March 2019. Ganetespib, developed by Synta Pharmaceuticals,  is an investigational drug that inhibits heat shock protein 90 (HSP90), a molecular chaperone essential for the proper maturation and activation of a number of proteins, many of which are important in cell growth, differentiation, and survival. Cancer cells need higher levels of HSP90, and therefore are more sensitive to HSP90 inhibitors. "For the first time, using the Parsortix system, we can now reliably access ovarian cancer cells from patient blood samples for analysis," Professor Robert Zeillinger, head of the molecular oncology group at the Medical University of Vienna, said in a
Subscribe or to access all post and page content.